Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | F10 | P00742 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BRD1 | O95696 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2473827 | 0.94 | F2 (0.41) | F2F10NPC1ALDH1A1TDP1 | |
| SCHEMBL3680306 | 0.84 | ALDH1A1 (0.40) | NPC1ALDH1A1TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL2594260 | 0.83 | CYP1A2 (0.47) | NPC1ALDH1A1TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL3643269 | 0.82 | ALDH1A1 (0.40) | NPC1ALDH1A1TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL2471712 | 0.82 | RAB9A (0.38) | F2F10ALDH1A1TDP1MAPK1 | |
| SCHEMBL2473536 | 0.81 | F2 (0.48) | F2F10ALDH1A1MAPTMEN1 | |
| SCHEMBL3808457 | 0.81 | F2 (0.46) | F2F10BRD1TAF1BRPF1 | |
| SCHEMBL2475612 | 0.81 | NPC1 (0.42) | NPC1ALDH1A1TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL2473208 | 0.80 | GAA (0.43) | ALDH1A1TDP1MAPK1SMN1; SMN2PKM | |
| SCHEMBL3424163 | 0.79 | ALDH1A1 (0.45) | NPC1ALDH1A1TDP1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846934-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846934-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-8487111-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8487111-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8487111-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8383822-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-8383822-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-8383822-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20100261759-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261759-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2173744-A1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | Bayer HealthCare AG (DE) | 2010-04-14 | — | — | EP | disclosed |
| EP-2170877-A1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | Bayer HealthCare AG (DE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008155033-A1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155032-A1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155032-A1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | F2 30/4885F10 360/4885NPC1 2465/4885 |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | F2 30/4885F10 360/4885NPC1 2465/4885 |
| US-20100261759-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | F2 30/4885F10 360/4885NPC1 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.